KR102087017B1 - 항체-약물 콘주게이트 - Google Patents

항체-약물 콘주게이트 Download PDF

Info

Publication number
KR102087017B1
KR102087017B1 KR1020197035246A KR20197035246A KR102087017B1 KR 102087017 B1 KR102087017 B1 KR 102087017B1 KR 1020197035246 A KR1020197035246 A KR 1020197035246A KR 20197035246 A KR20197035246 A KR 20197035246A KR 102087017 B1 KR102087017 B1 KR 102087017B1
Authority
KR
South Korea
Prior art keywords
antibody
group
amino acid
compound
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197035246A
Other languages
English (en)
Korean (ko)
Other versions
KR20190135559A (ko
Inventor
다케시 마스다
히로유키 나이토
다카시 나카다
마사오 요시다
신지 아시다
히데키 미야자키
유지 가스야
고지 모리타
유키 아베
유스케 오기타니
Original Assignee
다이이찌 산쿄 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50477169&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102087017(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 다이이찌 산쿄 가부시키가이샤 filed Critical 다이이찌 산쿄 가부시키가이샤
Publication of KR20190135559A publication Critical patent/KR20190135559A/ko
Application granted granted Critical
Publication of KR102087017B1 publication Critical patent/KR102087017B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D459/00—Heterocyclic compounds containing benz [g] indolo [2, 3-a] quinolizine ring systems, e.g. yohimbine; 16, 18-lactones thereof, e.g. reserpic acid lactone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
KR1020197035246A 2012-10-11 2013-10-10 항체-약물 콘주게이트 Active KR102087017B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012225887 2012-10-11
JPJP-P-2012-225887 2012-10-11
PCT/JP2013/006069 WO2014057687A1 (ja) 2012-10-11 2013-10-10 抗体－薬物コンジュゲート

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187026771A Division KR102052319B1 (ko) 2012-10-11 2013-10-10 항체-약물 콘주게이트

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207006240A Division KR102237639B1 (ko) 2012-10-11 2013-10-10 항체-약물 콘주게이트

Publications (2)

Publication Number Publication Date
KR20190135559A KR20190135559A (ko) 2019-12-06
KR102087017B1 true KR102087017B1 (ko) 2020-03-10

Family

ID=50477169

Family Applications (15)

Application Number Title Priority Date Filing Date
KR1020237004110A Active KR102540419B1 (ko) 2012-10-11 2013-10-10 글리신아미드 화합물의 제조 방법
KR1020237018596A Active KR102584005B1 (ko) 2012-10-11 2013-10-10 글리신아미드 화합물의 제조 방법
KR1020227006326A Active KR102417310B1 (ko) 2012-10-11 2013-10-10 글리신아미드 화합물의 제조 방법
KR1020227022424A Active KR102456726B1 (ko) 2012-10-11 2013-10-10 글리신아미드 화합물의 제조 방법
KR1020237032467A Active KR102709509B1 (ko) 2012-10-11 2013-10-10 글리신아미드 화합물의 제조 방법
KR1020157007536A Active KR101841818B1 (ko) 2012-10-11 2013-10-10 항체-약물 콘주게이트
KR1020187026771A Active KR102052319B1 (ko) 2012-10-11 2013-10-10 항체-약물 콘주게이트
KR1020227035813A Active KR102498405B1 (ko) 2012-10-11 2013-10-10 글리신아미드 화합물의 제조 방법
KR1020217034817A Active KR102369419B1 (ko) 2012-10-11 2013-10-10 글리신아미드 화합물의 제조 방법
KR1020207006240A Active KR102237639B1 (ko) 2012-10-11 2013-10-10 항체-약물 콘주게이트
KR1020247031228A Active KR102853456B1 (ko) 2012-10-11 2013-10-10 글리신아미드 화합물의 제조 방법
KR1020187007575A Active KR101901558B1 (ko) 2012-10-11 2013-10-10 항체-약물 콘주게이트
KR1020197035246A Active KR102087017B1 (ko) 2012-10-11 2013-10-10 항체-약물 콘주게이트
KR1020217009640A Active KR102320907B1 (ko) 2012-10-11 2013-10-10 글리신아미드 화합물의 제조 방법
KR1020257028036A Pending KR20250130442A (ko) 2012-10-11 2013-10-10 글리신아미드 화합물의 제조 방법

Family Applications Before (12)

Application Number Title Priority Date Filing Date
KR1020237004110A Active KR102540419B1 (ko) 2012-10-11 2013-10-10 글리신아미드 화합물의 제조 방법
KR1020237018596A Active KR102584005B1 (ko) 2012-10-11 2013-10-10 글리신아미드 화합물의 제조 방법
KR1020227006326A Active KR102417310B1 (ko) 2012-10-11 2013-10-10 글리신아미드 화합물의 제조 방법
KR1020227022424A Active KR102456726B1 (ko) 2012-10-11 2013-10-10 글리신아미드 화합물의 제조 방법
KR1020237032467A Active KR102709509B1 (ko) 2012-10-11 2013-10-10 글리신아미드 화합물의 제조 방법
KR1020157007536A Active KR101841818B1 (ko) 2012-10-11 2013-10-10 항체-약물 콘주게이트
KR1020187026771A Active KR102052319B1 (ko) 2012-10-11 2013-10-10 항체-약물 콘주게이트
KR1020227035813A Active KR102498405B1 (ko) 2012-10-11 2013-10-10 글리신아미드 화합물의 제조 방법
KR1020217034817A Active KR102369419B1 (ko) 2012-10-11 2013-10-10 글리신아미드 화합물의 제조 방법
KR1020207006240A Active KR102237639B1 (ko) 2012-10-11 2013-10-10 항체-약물 콘주게이트
KR1020247031228A Active KR102853456B1 (ko) 2012-10-11 2013-10-10 글리신아미드 화합물의 제조 방법
KR1020187007575A Active KR101901558B1 (ko) 2012-10-11 2013-10-10 항체-약물 콘주게이트

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020217009640A Active KR102320907B1 (ko) 2012-10-11 2013-10-10 글리신아미드 화합물의 제조 방법
KR1020257028036A Pending KR20250130442A (ko) 2012-10-11 2013-10-10 글리신아미드 화합물의 제조 방법

Country Status (30)

Country Link
US (6) US10195288B2 (enExample)
EP (3) EP3632471A1 (enExample)
JP (9) JP5953378B2 (enExample)
KR (15) KR102540419B1 (enExample)
CN (4) CN115960111A (enExample)
AU (5) AU2013328111B2 (enExample)
BR (3) BR122021014396B1 (enExample)
CA (2) CA2885800C (enExample)
CY (2) CY1120363T1 (enExample)
DK (2) DK3342785T3 (enExample)
ES (2) ES2671644T3 (enExample)
HR (2) HRP20180870T1 (enExample)
HU (2) HUE039000T2 (enExample)
IL (5) IL302494B2 (enExample)
LT (2) LT3342785T (enExample)
MX (3) MX364484B (enExample)
MY (1) MY170251A (enExample)
NZ (4) NZ746440A (enExample)
PH (2) PH12015500667B1 (enExample)
PL (2) PL3342785T3 (enExample)
PT (2) PT2907824T (enExample)
RS (2) RS57278B1 (enExample)
RU (1) RU2664465C2 (enExample)
SG (2) SG11201502887WA (enExample)
SI (2) SI2907824T1 (enExample)
SM (2) SMT202000138T1 (enExample)
TR (1) TR201809636T4 (enExample)
TW (14) TWI879657B (enExample)
WO (1) WO2014057687A1 (enExample)
ZA (2) ZA201501825B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024014837A1 (ko) 2022-07-11 2024-01-18 주식회사 피노바이오 Ddx5 단백질에 결합하는 캄토테신 유도체 및 이의 프로드럭

Families Citing this family (205)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL302494B2 (en) * 2012-10-11 2024-11-01 Daiichi Sankyo Co Ltd Antibody-drug conjugates and methods for their preparation
WO2014061277A1 (ja) 2012-10-19 2014-04-24 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート
KR102088169B1 (ko) * 2013-12-25 2020-03-12 다이이찌 산쿄 가부시키가이샤 항 trop2 항체-약물 컨쥬게이트
SMT202500030T1 (it) * 2014-01-31 2025-03-12 Daiichi Sankyo Co Ltd Coniugato anticorpo anti-her2-farmaco
JP2017114763A (ja) * 2014-03-26 2017-06-29 第一三共株式会社 抗ｃｄ９８抗体−薬物コンジュゲート
JP6612738B2 (ja) * 2014-04-10 2019-11-27 第一三共株式会社 抗ｈｅｒ２抗体−薬物コンジュゲート
PT3789042T (pt) * 2014-04-10 2025-01-14 Daiichi Sankyo Europe Gmbh Método para produzir conjugado anticorpo-fármaco anti-her3
WO2017002776A1 (ja) * 2015-06-29 2017-01-05 第一三共株式会社 抗体－薬物コンジュゲートの選択的製造方法
CN108779338A (zh) * 2015-12-24 2018-11-09 Ａｇｃ株式会社 树脂组合物、基材以及细胞培养方法
EP3442574A4 (en) * 2016-04-15 2019-12-11 MacroGenics, Inc. Novel B7-H3 binding MOLECULES, ANTIBODY-ACTIVE CONJUGATES AND METHOD OF USE THEREOF
CN109963870B (zh) * 2016-06-08 2023-07-28 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
CA3027044A1 (en) * 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
TW201825524A (zh) * 2016-09-20 2018-07-16 中國大陸商上海藥明生物技術有限公司 新型抗-pcsk9抗體
TW202508642A (zh) 2016-12-12 2025-03-01 日商第一三共股份有限公司 抗體-藥物結合物與免疫檢查點抑制劑之組合、以及醫藥組成物之用途
AU2018210081A1 (en) * 2017-01-17 2019-08-08 Daiichi Sankyo Company, Limited Anti-GPR20 antibody and anti-GPR20 antibody-drug conjugate
EP3590534A4 (en) 2017-02-28 2020-12-23 Kinki University METHOD OF TREATMENT OF EGFR-TKI-RESISTANT NON-SMALL-CELL LUNG CANCER BY ADMINISTRATION OF ANTI-HER3-DRUG ANTIBODY CONJUGATE
TW202532103A (zh) * 2017-05-15 2025-08-16 日商第一三共股份有限公司 抗體－藥物結合物及其用途
CN109963591B (zh) * 2017-08-04 2023-04-04 江苏恒瑞医药股份有限公司 B7h3抗体-药物偶联物及其医药用途
WO2019034176A1 (zh) * 2017-08-18 2019-02-21 四川百利药业有限责任公司 一种喜树碱-抗体偶联物
CA3073383C (en) * 2017-08-23 2023-10-31 Daiichi Sankyo Company, Limited Antibody-drug conjugate preparation and lyophilization for same
SG11202001514XA (en) 2017-08-31 2020-03-30 Daiichi Sankyo Co Ltd Novel method for producing antibody-drug conjugate
CN111051330A (zh) 2017-08-31 2020-04-21 第一三共株式会社 抗体-药物缀合物的改进制备方法
CN117003875A (zh) 2017-09-29 2023-11-07 第一三共株式会社 抗体或其功能性片段、多核苷酸、表达载体、宿主细胞、糖链重构抗体、药物组合物、应用
WO2019154120A1 (zh) * 2018-02-11 2019-08-15 四川科伦博泰生物医药股份有限公司 细胞毒性剂及其偶联物、其制备方法及用途
MA52669A (fr) * 2018-04-06 2021-02-17 Seagen Inc Conjugués peptidiques de camptothécine
SG11202010496WA (en) 2018-05-18 2020-12-30 Daiichi Sankyo Co Ltd Anti-muc1 antibody-drug conjugate
AU2019287765A1 (en) 2018-06-15 2021-01-07 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
EP3828206A4 (en) 2018-07-25 2022-04-20 Daiichi Sankyo Company, Limited METHOD OF PREPARING AN ANTIBODY DRUG CONJUGATE
US12358999B2 (en) 2018-07-27 2025-07-15 Daiichi Sankyo Company, Limited Protein recognizing drug moiety of antibody-drug conjugate
US12220604B2 (en) * 2018-07-31 2025-02-11 Daiichi Sankyo Company, Limited Treatment of metastatic brain tumor by administration of an antibody-drug conjugate
EA202190471A1 (ru) 2018-08-06 2021-05-24 Дайити Санкио Компани, Лимитед Комбинация конъюгата антитела-лекарственного средства и ингибитора тубулина
CN112739826A (zh) 2018-08-23 2021-04-30 第一三共株式会社 抗体-药物缀合物的敏感性标志物
PT3848054T (pt) 2018-09-06 2025-04-03 Daiichi Sankyo Co Ltd Conjugados anticorpo-fármaco de derivados de dinucleótidos cíclicos
TW202024133A (zh) 2018-09-20 2020-07-01 日商第一三共股份有限公司 利用投予抗her3抗體-藥物結合物之her3突變癌之治療
WO2020063676A1 (zh) 2018-09-26 2020-04-02 江苏恒瑞医药股份有限公司 依喜替康类似物的配体-药物偶联物及其制备方法和应用
MX2021003446A (es) 2018-09-30 2021-06-15 Jiangsu Hansoh Pharmaceutical Group Co Ltd Conjugado analogo del anticuerpo anti-bth3 y exatecan, y uso medicinal del mismo.
JP7401456B2 (ja) 2018-11-14 2023-12-19 第一三共株式会社 抗ｃｄｈ６抗体－ピロロベンゾジアゼピン誘導体コンジュゲート
CN113271942A (zh) * 2018-12-11 2021-08-17 第一三共株式会社 抗体-药物缀合物与parp抑制剂的组合
KR20210107069A (ko) 2018-12-21 2021-08-31 다이이찌 산쿄 가부시키가이샤 항체-약물 컨쥬게이트와 키나아제 저해제의 조합
CA3134056A1 (en) 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 bispecific antibodies
SI3941946T1 (sl) 2019-03-20 2025-09-30 The Regents Of The University Of California Protitelesa proti klavdinu-6 in konjugati zdravil
EP3946464B1 (en) 2019-03-29 2022-08-31 MedImmune Limited Compounds and conjugates thereof
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
CN111689980A (zh) * 2019-05-26 2020-09-22 四川百利药业有限责任公司 一种喜树碱药物及其抗体偶联物
CN113766933B (zh) * 2019-06-28 2024-09-06 上海复旦张江生物医药股份有限公司 一种抗体偶联药物、其中间体、制备方法及应用
CN112138171B (zh) * 2019-06-28 2024-09-24 泰州复旦张江药业有限公司 抗体偶联药物、其中间体、制备方法及应用
CN114341162B (zh) 2019-07-10 2025-10-17 赛博克萨2公司 作为治疗剂的细胞毒素的肽缀合物
US11555019B2 (en) 2019-07-10 2023-01-17 Cybrexa 3, Inc. Peptide conjugates of microtubule-targeting agents as therapeutics
AU2020347715A1 (en) * 2019-09-18 2022-04-07 Systimmune, Inc. Camptothecin derivative and conjugate thereof
BR112022011032A2 (pt) 2019-12-12 2022-08-16 Jiangsu Hengrui Medicine Co Conjugado de anticorpo-fármaco anti-claudina e uso farmacêutico do mesmo
CN118453897A (zh) * 2019-12-16 2024-08-09 江苏恒瑞医药股份有限公司 抗cea抗体-依喜替康类似物偶联物及其医药用途
EP4076434A1 (en) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
AU2021210074A1 (en) 2020-01-22 2022-07-28 Jiangsu Hengrui Medicine Co., Ltd. Anti-TROP-2 antibody-exatecan analog conjugate and medical use thereof
BR112022014398A2 (pt) 2020-01-22 2022-09-13 Shanghai Senhui Medicine Co Ltd Conjugado de fármaco de derivado de eribulina, método de preparação para o mesmo e aplicação do mesmo em medicina
WO2021173773A1 (en) 2020-02-25 2021-09-02 Mediboston, Inc. Camptothecin derivatives and conjugates thereof
JPWO2021177438A1 (enExample) 2020-03-06 2021-09-10
WO2021190480A1 (zh) * 2020-03-24 2021-09-30 上海翰森生物医药科技有限公司 抗体-药物偶联物及其医药用途
CA3175048A1 (en) 2020-03-25 2021-09-30 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Preparation method for antibody medicament conjugate
CA3175733A1 (en) * 2020-03-25 2021-09-30 Shanghai Hengrui Pharmaceutical Co., Ltd. Pharmaceutical composition comprising antibody drug conjugate and use thereof
CN115298186B (zh) * 2020-03-25 2024-09-13 江苏恒瑞医药股份有限公司 抗psma抗体-依喜替康类似物偶联物及其医药用途
EP4130036A4 (en) 2020-03-30 2024-05-15 National Cancer Center Antibody drug conjugate
EP4162954A4 (en) * 2020-06-08 2025-05-07 SystImmune, Inc. Camptothecin drug having high-stability hydrophilic connecting unit and conjugate thereof
WO2021260582A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and aurora b inhibitor
KR20230043109A (ko) 2020-06-24 2023-03-30 아스트라제네카 유케이 리미티드 항체-약물 접합체 및 atr 억제제의 조합
EP4171654A1 (en) 2020-06-24 2023-05-03 AstraZeneca UK Limited Combination of antibody-drug conjugate and cdk9 inhibitor
US20230256110A1 (en) 2020-06-24 2023-08-17 Astrazeneca Uk Limited Combination of antibody-drug conjugate and atm inhibitor
WO2021260583A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and dna-pk inhibitor
CA3184366A1 (en) 2020-06-29 2022-01-06 Darby Rye Schmidt Viruses engineered to promote thanotransmission and their use in treating cancer
US11361026B2 (en) 2020-06-30 2022-06-14 Snowflake Inc. Accessing files in a database stage using a user defined function
US11423081B1 (en) 2020-06-30 2022-08-23 Snowflake Inc. Accessing files in a database stage using a user defined function
US10997243B1 (en) 2020-06-30 2021-05-04 Snowflake Inc. Supporting unstructured, semi-structured, and structured files
AU2021306557A1 (en) 2020-07-06 2023-02-02 Byondis B.V. Antifolate linker-drugs and antibody-drug conjugates
US20230293712A1 (en) * 2020-07-10 2023-09-21 VelosBio Inc. Novel ror1 antibody immunoconjugates
IL299153A (en) * 2020-07-13 2023-02-01 Regeneron Pharma Camptothecin analogs conjugated to a glutamine residue in protein, and their uses
JPWO2022014698A1 (enExample) 2020-07-17 2022-01-20
KR20230050378A (ko) 2020-08-13 2023-04-14 이나뜨 파르마 에스.에이. 항-cd73 항체를 사용하여 암을 치료하는 방법
WO2022033578A1 (zh) * 2020-08-13 2022-02-17 正大天晴药业集团股份有限公司 抗体药物偶联物
TW202227479A (zh) 2020-09-02 2022-07-16 日商第一三共股份有限公司 新穎內－β－Ｎ－乙醯葡萄糖胺苷酶
EP4223318A4 (en) 2020-09-30 2024-12-18 Duality Biologics (Suzhou) Co., Ltd. Antitumor compound, and preparation method therefor and use thereof
WO2022074617A1 (en) 2020-10-09 2022-04-14 Astrazeneca Uk Limited Combination of antibody-drug conjugate and parp1 selective inhibitor
US20250276078A1 (en) * 2020-10-12 2025-09-04 Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. Camptothecin Derivative And Ligand-drug Conjugate Thereof
WO2022078259A1 (zh) * 2020-10-12 2022-04-21 四川百利药业有限责任公司 一种氘代的喜树碱衍生物及其抗体药物偶联物
KR20230106645A (ko) 2020-11-11 2023-07-13 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트와 항 SIRPα 항체의 조합
WO2022099762A1 (zh) * 2020-11-12 2022-05-19 博瑞生物医药（苏州）股份有限公司 一种抗体偶联物中间体及其制备方法
CA3198382A1 (en) 2020-11-12 2022-05-19 Michiko Yamato Treatment of mesothelioma by administration of anti-b7-h3 antibody-drug conjugate
AU2020482223A1 (en) * 2020-12-18 2023-07-27 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Trop2 targeting antibody-drug conjugate, and preparation method and use therefor
JP7564958B2 (ja) * 2020-12-18 2024-10-09 シャンハイ フダン－チャンジャン バイオ－ファーマシューティカル カンパニー リミテッド Ｂ７－ｈ３を標的とする抗体薬物複合体、その製造方法と使用
US20240066138A1 (en) * 2020-12-23 2024-02-29 Shanghai Ruotuo Biosciences Co., Ltd. Antibody-drug conjugates, pharmaceutical compositions, and therapeutic applications
CN117425500A (zh) 2021-01-13 2024-01-19 纪念斯隆凯特琳癌症中心 抗dll3抗体-药物缀合物
CN114805377A (zh) * 2021-01-29 2022-07-29 明慧医药（杭州）有限公司 适用于抗体-药物偶联物的毒素分子
TW202241454A (zh) 2021-02-01 2022-11-01 日商第一三共股份有限公司 抗體－免疫賦活化劑共軛物之新穎製造方法
CN120093941A (zh) 2021-02-09 2025-06-06 苏州宜联生物医药有限公司 生物活性物偶联物及其制备方法和用途
CA3212691A1 (en) 2021-03-12 2022-09-15 Daiichi Sankyo Company, Limited Glycan, and method for producing medicine containing glycan
CN117015549A (zh) * 2021-03-17 2023-11-07 江苏恒瑞医药股份有限公司 一种喜树碱衍生物的制备方法
US12036286B2 (en) 2021-03-18 2024-07-16 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
JP2024512669A (ja) 2021-03-31 2024-03-19 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用
CN115197234A (zh) * 2021-04-02 2022-10-18 江苏恒瑞医药股份有限公司 一种喜树碱衍生物中间体的制备方法
CA3215049A1 (en) 2021-04-10 2022-10-13 Baiteng ZHAO Folr1 binding agents, conjugates thereof and methods of using the same
EP4323009A4 (en) * 2021-04-14 2025-03-05 Genequantum Healthcare (Suzhou) Co., Ltd. Linkers, conjugates and applications thereof
EP4079327A1 (en) 2021-04-22 2022-10-26 Centaurus Polytherapeutics Payloads for drug-conjugates and their use for treating cancer
JP7742892B2 (ja) 2021-04-23 2025-09-22 ジェンマブ エー／エス 抗ｃｄ７０抗体、そのコンジュゲートおよびこれを使用する方法
MX2023012456A (es) * 2021-04-26 2023-10-31 Jiangsu Hengrui Pharmaceuticals Co Ltd Anticuerpo anti-nectina-4 y conjugado anticuerpo-farmaco anti-nectina-4-, y uso medicinal del mismo.
CN113816969B (zh) * 2021-04-30 2024-01-16 联宁（苏州）生物制药有限公司 依喜替康类化合物、其抗体药物偶联物及其应用
US11645243B2 (en) 2021-06-07 2023-05-09 Snowflake Inc. Accessing files in a database stage using a user defined function
CA3223304A1 (en) * 2021-06-17 2022-12-22 Minghui Pharmaceutical (Hangzhou) Limited Antitumor compound and its application
IL309249A (en) 2021-06-28 2024-02-01 Byondis Bv Conjugates including phosphoantigens and their use in therapy
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
CN113402584A (zh) * 2021-07-06 2021-09-17 联宁（苏州）生物制药有限公司 一种抗体偶联药物连接子的中间体lnd1067-l1的合成方法
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
CN113527418B (zh) * 2021-07-16 2022-05-03 成都普康唯新生物科技有限公司 一种ADC linker的制备方法
IL309884A (en) * 2021-07-19 2024-03-01 Zeno Man Inc Immunoconjugates and methods
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
AU2022314086A1 (en) 2021-07-21 2024-02-22 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition containing anti-trop2 antibody drug conjugate and use thereof
MX2024003277A (es) 2021-09-15 2024-04-04 Daiichi Sankyo Co Ltd Conjugado de anticuerpo-farmaco para usarse en metodos de tratamiento del cancer resistente a la quimioterapia.
EP4410830A1 (en) 2021-09-30 2024-08-07 Ajinomoto Co., Inc. Conjugate of antibody and functional substance or salt thereof, and antibody derivative and compound or salts thereof to be used in producing conjugate or salt thereof
AU2022368385A1 (en) 2021-10-18 2024-04-11 Daiichi Sankyo Company, Limited Anti-cd37 antibody-drug conjugate
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
MX2024005831A (es) 2021-11-15 2024-07-09 Systimmune Inc Conjugado de anticuerpo biespecifico-farmaco de camptotecina y uso farmaceutico del mismo.
US11814394B2 (en) * 2021-11-16 2023-11-14 Genequantum Healthcare (Suzhou) Co., Ltd. Exatecan derivatives, linker-payloads, and conjugates and thereof
CN118414173A (zh) 2021-11-18 2024-07-30 阿斯利康(英国)有限公司 抗体-药物缀合物和parp1选择性抑制剂的组合
EP4433096A1 (en) 2021-11-19 2024-09-25 Ardeagen Corporation Gpc3 binding agents, conjugates thereof and methods of using the same
KR20240113514A (ko) 2021-11-30 2024-07-22 다이이찌 산쿄 가부시키가이샤 프로테아제 분해성 마스크 항체
IL313262A (en) 2021-12-03 2024-08-01 Systimmune Inc Anti-human trop2 antibody-camptothecin drug conjugate and medical use thereof
KR20240125958A (ko) 2021-12-23 2024-08-20 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 항-dll3 항체, 이의 항체-약물 접합체 및 이의 의약적 용도
CN116333135A (zh) * 2021-12-24 2023-06-27 百奥泰生物制药股份有限公司 抗FRα抗体及其抗体药物偶联物和用途
MX2024008000A (es) 2021-12-28 2024-07-12 Astrazeneca Uk Ltd Combinacion de conjugado de anticuerpo-farmaco e inhibidor de cinasa relacionada con ataxia telangiectasia y rad3 (atr).
EP4456899A1 (en) 2021-12-28 2024-11-06 AstraZeneca UK Limited Combination of antibody-drug conjugate and rasg12c inhibitor
CA3242777A1 (en) 2021-12-30 2023-07-06 Byondis B.V. Antifolate linker-drugs and antibody-drug conjugates
US20250161473A1 (en) * 2022-01-18 2025-05-22 Gan & Lee Pharmaceuticals Co., Ltd. Exatecan derivative-antibody conjugate and medical use thereof
CN118891283A (zh) 2022-01-25 2024-11-01 苏州宜联生物医药有限公司 一种针对Her3的抗体，偶联物及其用途
JPWO2023153442A1 (enExample) 2022-02-09 2023-08-17
WO2023163227A1 (ja) 2022-02-28 2023-08-31 Ｕｂｅ株式会社 抗体－薬物コンジュゲート
US20250170267A1 (en) 2022-02-28 2025-05-29 Ube Corporation Antibody-drug conjugate precursor and intermediate for synthesis thereof
EP4488378A1 (en) 2022-03-02 2025-01-08 Daiichi Sankyo Company, Limited Method for producing fc-containing molecule
JP2025509286A (ja) 2022-03-10 2025-04-11 ビバソル， インコーポレイテッド 抗体－薬物コンジュゲートおよびその使用
KR20240165390A (ko) 2022-03-16 2024-11-22 아스트라제네카 유케이 리미티드 항-trop2 항체-약물 접합체 요법에 대한 점수산정 방법
TWI864640B (zh) 2022-03-18 2024-12-01 大陸商映恩生物製藥（蘇州）有限公司 Gpc3抗體藥物偶聯物及其用途
JP2025512466A (ja) 2022-04-12 2025-04-17 ミネルバ バイオテクノロジーズ コーポレーション 抗可変ｍｕｃ１＊抗体およびその使用
WO2023209591A1 (en) 2022-04-27 2023-11-02 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor
TW202400650A (zh) 2022-05-11 2024-01-01 日商第一三共股份有限公司 抗體與cd47抑制劑之組合
AU2023274540A1 (en) 2022-05-24 2024-12-12 Daiichi Sankyo Company, Limited Dosage regimen of an anti-cdh6 antibody-drug conjugate
WO2023234427A1 (ja) 2022-06-03 2023-12-07 Ｕｂｅ株式会社 抗体・複数薬物コンジュゲート前駆体およびその合成中間体
JPWO2023234426A1 (enExample) 2022-06-03 2023-12-07
KR20250021316A (ko) 2022-06-07 2025-02-12 듀얼리티 바이올로직스 (쑤저우) 컴퍼니 리미티드 항-b7h3 항체-약물 접합체 및 이의 용도
JP2025519421A (ja) * 2022-06-09 2025-06-26 ベイジーン スイッツァランド ゲーエムベーハー 抗体薬物複合体
US20250367311A1 (en) 2022-06-15 2025-12-04 Shanghai Hansoh Biomedical Co., Ltd. Pharmaceutical composition containing an antibody-drug conjugate and use thereof
CN115160403B (zh) * 2022-07-05 2025-06-27 博石丰生命科技(南通)有限公司 特异性拓扑异构酶抑制剂和可用于抗体药物偶联物及其制备方法
CN118955615A (zh) * 2022-07-05 2024-11-15 上海药明合联生物技术有限公司 偶联连接子
EP4556026A1 (en) 2022-07-14 2025-05-21 Medilink Therapeutics (Suzhou) Co., Ltd. Antibody-drug conjugate, and preparation method therefor and use thereof
CA3262069A1 (en) 2022-07-15 2024-01-18 Genequantum Healthcare (Suzhou) Co., Ltd. ANTIBODIES, BINDERS, PAYLOAD, CONJUGATES AND THEIR APPLICATIONS
CA3262616A1 (en) * 2022-07-22 2024-01-25 Nj Bio, Inc. HEXACYCLIC TOPOISOMERASE INHIBITORS WITH CYTOTOXIC ACTIVITY ON CANCER CELLS
EP4563163A1 (en) 2022-07-27 2025-06-04 Minghui Pharmaceutical (Hangzhou) Limited Antibody-drug conjugate and use thereof
CN117510515A (zh) * 2022-07-28 2024-02-06 明慧医药（杭州）有限公司 适用于抗体-药物偶联物的毒素分子
WO2024023750A1 (en) 2022-07-28 2024-02-01 Astrazeneca Uk Limited Combination of antibody-drug conjugate and bispecific checkpoint inhibitor
WO2024027708A1 (zh) 2022-08-02 2024-02-08 诺纳生物（苏州）有限公司 Msln抗体药物偶联物
CN119730886A (zh) 2022-08-25 2025-03-28 启德医药科技（苏州）有限公司 抗体偶联药物的药物组合物
CN119744182A (zh) 2022-08-29 2025-04-01 第一三共株式会社 包含突变Fc区的抗体药物偶联物
CN120225528A (zh) 2022-09-02 2025-06-27 默沙东有限责任公司 依喜替康衍生的拓扑异构酶-1抑制剂药物组合物及其用途
TW202419107A (zh) 2022-09-09 2024-05-16 日商第一三共股份有限公司 新穎寡醣、該寡醣之製造中間體、及彼等之製造方法
CN117752813A (zh) 2022-09-26 2024-03-26 成都百利多特生物药业有限责任公司 抗cd33抗体和抗cd33抗体-药物偶联物及其用途
CN120265285A (zh) * 2022-09-26 2025-07-04 索尔夫治疗公司 组合物及其用途
IL319866A (en) * 2022-09-30 2025-05-01 Beigene Switzerland Gmbh Ligand-drug conjugates of exatacan analogs and their medical use
EP4598946A1 (en) 2022-10-05 2025-08-13 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024078449A1 (en) 2022-10-09 2024-04-18 LaNova Medicines Limited Compounds, compositions and methods
PE20251547A1 (es) 2022-10-25 2025-06-05 Merck Sharp And Dohme Llc Enlazadores-cargas utiles de adc derivados de exatecan, composiciones farmaceuticas, y usos de los mismos
KR20250111207A (ko) 2022-11-24 2025-07-22 비원 메디슨즈 아이 게엠베하 항체 약물 접합체
AU2023387509A1 (en) * 2022-11-25 2025-07-10 Minghui Pharmaceutical (Hangzhou) Limited An anti-tumor compound and use thereof
CN118105508A (zh) * 2022-11-29 2024-05-31 四川科伦博泰生物医药股份有限公司 药物连接子化合物及其制备方法和用途
JP2025540063A (ja) 2022-11-30 2025-12-11 第一三共株式会社 抗体－薬物コンジュゲートおよびｄｎｍｔ阻害剤の併用
CN116621927B (zh) * 2023-01-09 2024-03-26 联宁（苏州）生物制药有限公司 带有伊喜替康和C-lock定点偶联基团的抗体偶联中间体、偶联方法及抗体偶联药物
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
KR20250145079A (ko) 2023-02-09 2025-10-13 비원 메디슨즈 아이 게엠베하 자가 안정화 링커 접합체
KR20250153805A (ko) * 2023-02-27 2025-10-27 쑤저우 선카디아 바이오파마수티컬즈 컴퍼니 리미티드 항-dll3 항체, 이의 항체-약물 접합체 및 이의 의약적 용도
KR20250170141A (ko) 2023-03-14 2025-12-04 다이이찌 산쿄 가부시키가이샤 항 cdh6 항체-약물 콘주게이트와 vegf 저해제의 조합
CN118666946A (zh) * 2023-03-15 2024-09-20 上海亲合力生物医药科技股份有限公司 连接子及使用其的偶联药物、抗体偶联药物及其应用
CN120957753A (zh) * 2023-03-23 2025-11-14 广州百济神州生物制药有限公司 生物活性结合物、其制备方法和其用途
WO2024204629A1 (ja) 2023-03-29 2024-10-03 第一三共株式会社 抗ｃｄ２５抗体及び抗ｃｄ２５抗体－薬物コンジュゲート
CN120916791A (zh) 2023-03-31 2025-11-07 第一三共株式会社 抗CDH6抗体-药物缀合物与HIF-2α抑制剂的组合
KR20250172615A (ko) 2023-04-04 2025-12-09 아지노모토 가부시키가이샤 항체 및 기능성 물질의 컨쥬게이트, 항체 유도체 및 화합물, 또는 그것들의 염
WO2024211235A1 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
WO2024211236A2 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
TW202506190A (zh) 2023-04-05 2025-02-16 日商第一三共股份有限公司 利用抗ｍｕｃ１抗體－藥物結合物投予的藥劑低敏感性癌之治療方法
CN121039143A (zh) 2023-04-05 2025-11-28 味之素株式会社 抗体和功能性物质的缀合物或其盐、以及具有硫醇基的抗体中间体或其盐
WO2024211234A1 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
WO2024214685A1 (ja) 2023-04-10 2024-10-17 第一三共株式会社 抗ｂ７－ｈ３抗体－薬物コンジュゲートとａｔｒ阻害剤又はａｔｍ阻害剤との組み合わせ
WO2024213091A1 (en) 2023-04-13 2024-10-17 Genequantum Healthcare (Suzhou) Co., Ltd. Combination of antibody-drug conjugate and anti-pd-1 antibody, and use thereof
CN121057735A (zh) * 2023-05-06 2025-12-02 上海齐鲁制药研究中心有限公司 一种氘代喜树碱化合物及其制备和应用
WO2024230752A1 (zh) 2023-05-08 2024-11-14 甘李药业股份有限公司 喜树碱衍生物、接头、配体-药物偶联物及其医药用途
WO2024235071A1 (en) * 2023-05-16 2024-11-21 Nanjing University Conjugate and the preparation thereof
AU2024273972A1 (en) * 2023-05-16 2025-12-04 CSPC Megalith Biopharmaceutical Co., Ltd. Pharmaceutical composition comprising antibody-drug conjugate
WO2025002310A1 (zh) * 2023-06-29 2025-01-02 石药集团巨石生物制药有限公司 抗体-药物偶联物及其用途
WO2025005240A1 (ja) * 2023-06-30 2025-01-02 第一三共株式会社 活性炭材料を使用する精製工程を含む抗体－薬物コンジュゲートの製造方法
CN119490559A (zh) * 2023-08-16 2025-02-21 中山康方生物医药有限公司 化合物以及含有该化合物的抗体偶联药物
TW202535954A (zh) 2023-09-26 2025-09-16 丹麥商珍美寶股份有限公司 Ｐｔｋ７結合劑、其共軛物及使用彼等之方法
WO2025088496A1 (en) 2023-10-24 2025-05-01 Astrazeneca Uk Limited Combination of antibody-drug conjugate and anti-pd-1/tim-3 bispecific binding protein
WO2025106278A1 (en) 2023-11-17 2025-05-22 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates
TW202535479A (zh) 2023-12-05 2025-09-16 英商阿斯特捷利康英國股份有限公司 抗體藥物結合物與血腦屏障穿透性ｐａｒｐ１選擇性抑制劑之組合
WO2025141153A1 (en) 2023-12-29 2025-07-03 Oncomatryx Biopharma, S.L. Endo180 targeted antibody-drug conjugates
US20250222125A1 (en) 2024-01-05 2025-07-10 Beigene, Ltd. Anti-FGFR2b Antibodies, Conjugates and Methods of Use
US20250296992A1 (en) 2024-01-10 2025-09-25 Genmab A/S Slitrk6 binding agents, conjugates thereof and methods of using the same
WO2025181219A1 (en) 2024-02-29 2025-09-04 Genmab A/S Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
WO2025185559A1 (zh) * 2024-03-04 2025-09-12 杭州中美华东制药有限公司 抗FGFR2b抗体、其抗体药物偶联物及其用途
WO2025186213A1 (en) 2024-03-04 2025-09-12 Debiopharm International S.A. Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor
WO2025238587A1 (en) 2024-05-16 2025-11-20 Daiichi Sankyo Company, Limited Combination of anti-b7-h3 antibody-drug conjugate and androgen receptor signaling inhibitor
WO2025241867A1 (zh) * 2024-05-24 2025-11-27 明慧医药（杭州）有限公司 抗b7-h4抗体药物偶联物及其应用

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JP3008226B2 (ja) 1991-01-16 2000-02-14 第一製薬株式会社 六環性化合物
US5637770A (en) * 1991-01-16 1997-06-10 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic compound
JPH0559061U (ja) 1991-04-18 1993-08-03 株式会社ケイヴイシー ボールバルブ
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
DE69333823T2 (de) 1992-03-24 2006-05-04 Cambridge Antibody Technology Ltd., Melbourn Verfahren zur herstellung von gliedern von spezifischen bindungspaaren
JP3359955B2 (ja) 1992-07-16 2002-12-24 第一製薬株式会社 抗腫瘍剤
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
JPH0687746U (ja) 1993-06-02 1994-12-22 株式会社ユニシアジェックス 液圧緩衝器のリザーバチューブ構造
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
JPH09506508A (ja) 1993-12-03 1997-06-30 メディカル リサーチ カウンシル 組換え結合タンパク質およびペプチド
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US6504029B1 (en) 1995-04-10 2003-01-07 Daiichi Pharmaceutical Co., Ltd. Condensed-hexacyclic compounds and a process therefor
JPH08337584A (ja) 1995-04-10 1996-12-24 Dai Ichi Seiyaku Co Ltd 縮合六環式アミノ化合物、これを含有する医薬及びその製法
SG50747A1 (en) 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
CA2192725C (en) 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives
JPH1095802A (ja) 1995-12-28 1998-04-14 Tanabe Seiyaku Co Ltd カンプトテシン誘導体
TW409058B (en) 1996-06-06 2000-10-21 Daiichi Seiyaku Co Method for preparation of a drug complex
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
JPH1171280A (ja) 1997-06-26 1999-03-16 Tanabe Seiyaku Co Ltd 医薬組成物
JPH1192405A (ja) * 1997-09-19 1999-04-06 Dai Ichi Seiyaku Co Ltd 薬物複合体
PT2180007E (pt) 1998-04-20 2013-11-25 Roche Glycart Ag Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
EA003398B1 (ru) * 1998-05-22 2003-04-24 Дайити Фармасьютикал Ко., Лтд. Лекарственный комплекс c полимерным носителем
EP1155702A4 (en) 1998-10-30 2004-12-15 Daiichi Seiyaku Co DDS CONNECTIONS AND TEST METHODS
ES2568899T3 (es) 1999-04-09 2016-05-05 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
JP2002060351A (ja) 2000-03-22 2002-02-26 Dai Ichi Seiyaku Co Ltd 水酸基を有する薬物を含むｄｄｓ化合物
AU2001267831A1 (en) 2000-06-29 2002-01-08 Daiichi Pharmaceutical Co., Ltd. DDS compound and process for the preparation thereof
MXPA03000387A (es) 2000-07-13 2003-09-22 Daiichi Seiyaku Co Derivados de 4-fenil-piridina como antagonistas del receptor de neuroquinina-1.
EP1331266B1 (en) 2000-10-06 2017-01-04 Kyowa Hakko Kirin Co., Ltd. Cells producing antibody compositions
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
TWI313609B (en) 2001-08-21 2009-08-21 Mitsubishi Tanabe Pharma Corp Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor
RU2313368C2 (ru) 2001-11-01 2007-12-27 Ю Эй Би Рисерч Фаундейшн Комбинации антител, обладающих селективностью по отношению к рецептору лиганда, индуцирующему апоптоз, ассоциированный с фактором некроза опухоли, и других терапевтических средств
US20050123536A1 (en) 2001-11-20 2005-06-09 Che-Leung Law Treatment of immunological disorders using anti-dc30 antibodies
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
CA2478047C (en) 2002-03-01 2014-01-21 Immunomedics, Inc. Rs7 antibodies
US20050276812A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
AU2003288467A1 (en) 2002-12-13 2004-07-09 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
US20040202666A1 (en) 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
CN1964716A (zh) 2004-02-26 2007-05-16 伊诺泰克制药公司 异喹啉衍生物及其使用方法
WO2005084390A2 (en) 2004-03-02 2005-09-15 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
WO2005112919A2 (en) * 2004-05-19 2005-12-01 Medarex, Inc. Self-immolative linkers and drug conjugates
JP2008521828A (ja) * 2004-11-29 2008-06-26 シアトル ジェネティックス， インコーポレイテッド 操作された抗体およびイムノコンジュゲート
DE102005009084A1 (de) 2005-02-28 2006-08-31 Ktb Tumorforschungsgesellschaft Mbh Proteinbindende Anthrazyklin-Peptid-Derivate und diese enthaltende Arzneimittel
DE102005009099A1 (de) 2005-02-28 2006-08-31 Ktb Tumorforschungsgesellschaft Mbh Proteinbindende Camptothecin-Peptid-Derivate und diese enthaltende Arzneimittel
CN101203241B (zh) 2005-04-19 2012-02-22 西雅图基因公司 人源化抗-cd70结合物和其应用
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
SI2032606T1 (sl) * 2006-05-30 2014-02-28 Genentech, Inc. Protitelesa in imunokonjugati in njihove uporabe
RS54163B1 (sr) * 2006-05-30 2015-12-31 Genentech Inc. Anti-cd22 antitela, njihovi imunokonjugati i njihova upotreba
WO2007145306A1 (ja) 2006-06-15 2007-12-21 National University Corporation Hokkaido University 腫瘍組織で選択的に分解性を示す血中滞留性素子
ITMI20061473A1 (it) * 2006-07-26 2008-01-27 Indena Spa Derivati della camptotecina ad attivita antitumorale
CN101687838A (zh) 2006-12-21 2010-03-31 先灵公司 抑制ksp驱动蛋白活性的吡咯并[3,2-a]吡啶衍生物
EP2121008A4 (en) * 2007-03-22 2010-03-31 Sloan Kettering Inst Cancer USE OF MONOCLONAL ANTIBODY 8H9
KR101764927B1 (ko) 2008-04-30 2017-08-03 이뮤노젠 아이엔씨 가교제 및 그 용도
EP2393512B1 (en) 2009-02-05 2016-10-26 ONCOXX Biotech s.r.l. Anti-trop-2 monoclonal antibodies and uses thereof in the treatment and diagnosis of tumors
PL3939617T3 (pl) 2009-02-13 2025-03-17 Immunomedics, Inc. Związki pośrednie do wytwarzania koniugatów z wiązaniem rozszczepialnym wewnątrzkomórkowo
WO2011021397A1 (ja) 2009-08-20 2011-02-24 国立大学法人千葉大学 コルヒチン誘導体
JP2013505944A (ja) 2009-09-24 2013-02-21 シアトル ジェネティックス， インコーポレイテッド Ｄｒ５リガンド薬物結合体
JP6121323B2 (ja) 2010-05-13 2017-05-10 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 核内ホルモン受容体の活性を示すグルカゴンスーパーファミリーのペプチド
US20110300150A1 (en) 2010-05-18 2011-12-08 Scott Eliasof Compositions and methods for treatment of autoimmune and other disease
PE20130643A1 (es) 2010-07-12 2013-06-07 Covx Technologies Ireland Ltd Conjugados de anticuerpos multifuncionales
CA2816426A1 (en) 2010-11-17 2012-06-07 Genentech, Inc. Alaninyl maytansinol antibody conjugates
CA2954166A1 (en) 2011-11-11 2013-05-16 Rinat Neuroscience Corp. Antibodies specific for trop-2 and their uses
WO2013087716A2 (de) 2011-12-14 2013-06-20 Bayer Pharma Aktiengesellschaft Neue binder-wirkstoff konjugate (adcs) und ihre verwendung
US20130280282A1 (en) 2012-04-24 2013-10-24 Daiichi Sankyo Co., Ltd. Dr5 ligand drug conjugates
AU2013274078A1 (en) 2012-06-14 2015-01-29 Ambrx, Inc. Anti-PSMA antibodies conjugated to nuclear receptor ligand polypeptides
US9517522B2 (en) * 2012-09-05 2016-12-13 Illinois Tool Works Inc. Self-aligning wire feeder assembly
IL302494B2 (en) 2012-10-11 2024-11-01 Daiichi Sankyo Co Ltd Antibody-drug conjugates and methods for their preparation
WO2014061277A1 (ja) 2012-10-19 2014-04-24 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート
WO2014107024A1 (ko) 2013-01-03 2014-07-10 셀트리온 항체-링커-약물 결합체, 그의 제조방법 및 그를 포함하는 항암제 조성물
CN103313390B (zh) 2013-07-05 2016-01-20 江苏大学 一种基于双移动信标的wsn定位方法
SMT202500030T1 (it) 2014-01-31 2025-03-12 Daiichi Sankyo Co Ltd Coniugato anticorpo anti-her2-farmaco
JP6612738B2 (ja) 2014-04-10 2019-11-27 第一三共株式会社 抗ｈｅｒ２抗体−薬物コンジュゲート
KR102199434B1 (ko) 2017-02-24 2021-01-06 장길훈 대화형 애플리케이션의 메시지 공유 시스템과 방법

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024014837A1 (ko) 2022-07-11 2024-01-18 주식회사 피노바이오 Ddx5 단백질에 결합하는 캄토테신 유도체 및 이의 프로드럭

Also Published As

Publication number Publication date
BR112015006521B1 (pt) 2022-03-03
KR102709509B1 (ko) 2024-09-24
RS57278B1 (sr) 2018-08-31
CN113929738B (zh) 2024-05-17
CA2885800C (en) 2018-12-04
TW202448463A (zh) 2024-12-16
TW202448522A (zh) 2024-12-16
KR20180105271A (ko) 2018-09-27
CN104755494A (zh) 2015-07-01
KR20250130442A (ko) 2025-09-01
TW201811746A (zh) 2018-04-01
KR20220100727A (ko) 2022-07-15
AU2020200548A1 (en) 2020-02-13
US10973924B2 (en) 2021-04-13
TW202033499A (zh) 2020-09-16
TW202448523A (zh) 2024-12-16
KR20190135559A (ko) 2019-12-06
AU2013328111B2 (en) 2017-11-02
US20240082413A1 (en) 2024-03-14
IL302494B2 (en) 2024-11-01
JP6952835B2 (ja) 2021-10-27
KR20230024433A (ko) 2023-02-20
ES2773710T3 (es) 2020-07-14
HRP20200353T1 (hr) 2020-06-12
TW202444428A (zh) 2024-11-16
SMT201800344T1 (it) 2018-09-13
TWI696611B (zh) 2020-06-21
TW202448521A (zh) 2024-12-16
TWI757740B (zh) 2022-03-11
TW201920098A (zh) 2019-06-01
ZA201900820B (en) 2022-08-31
JP2017036274A (ja) 2017-02-16
SG11201502887WA (en) 2015-05-28
NZ705394A (en) 2018-10-26
PL2907824T3 (pl) 2018-08-31
TW202444366A (zh) 2024-11-16
IL238143B (en) 2020-01-30
KR20210132240A (ko) 2021-11-03
PH12015500667A1 (en) 2015-05-18
AU2020200548B2 (en) 2022-08-25
MX2015003903A (es) 2015-07-17
TWI877063B (zh) 2025-03-11
TWI879659B (zh) 2025-04-01
PH12015500667B1 (en) 2019-03-06
CA3021435C (en) 2021-10-12
TWI879656B (zh) 2025-04-01
TWI879657B (zh) 2025-04-01
RU2664465C2 (ru) 2018-08-17
MY170251A (en) 2019-07-13
DK3342785T3 (da) 2020-03-23
TWI870274B (zh) 2025-01-11
AU2022203560A1 (en) 2022-06-16
CY1120363T1 (el) 2019-07-10
HUE048748T2 (hu) 2020-08-28
JP2022008581A (ja) 2022-01-13
EP2907824B1 (en) 2018-04-11
HK1210477A1 (en) 2016-04-22
JP2023011799A (ja) 2023-01-24
PT3342785T (pt) 2020-02-25
JP2024147681A (ja) 2024-10-16
CN115960111A (zh) 2023-04-14
IL302494B1 (en) 2024-07-01
RU2018128384A (ru) 2018-10-02
BR122021014396B1 (pt) 2022-07-05
CN109081871B (zh) 2023-07-14
MX364484B (es) 2019-04-29
RU2015113767A (ru) 2016-12-10
US20160279259A1 (en) 2016-09-29
CN104755494B (zh) 2018-09-07
JP2020180124A (ja) 2020-11-05
TWI870275B (zh) 2025-01-11
EP3632471A1 (en) 2020-04-08
JP7523506B2 (ja) 2024-07-26
WO2014057687A1 (ja) 2014-04-17
KR20180030734A (ko) 2018-03-23
JP6030267B1 (ja) 2016-11-24
KR102237639B1 (ko) 2021-04-07
KR102456726B1 (ko) 2022-10-20
PT2907824T (pt) 2018-06-07
HUE039000T2 (hu) 2018-12-28
IL294622B2 (en) 2023-10-01
IL271760B (en) 2022-08-01
EP3342785A1 (en) 2018-07-04
JPWO2014057687A1 (ja) 2016-09-05
KR102320907B1 (ko) 2021-11-02
TW202444367A (zh) 2024-11-16
NZ746439A (en) 2019-11-29
KR102498405B1 (ko) 2023-02-09
IL238143A0 (en) 2015-05-31
RU2018128384A3 (enExample) 2021-12-20
KR101901558B1 (ko) 2018-09-21
CN113929738A (zh) 2022-01-14
BR112015006521A2 (enExample) 2017-09-05
IL302494A (en) 2023-06-01
HK1256631A1 (en) 2019-09-27
NZ740948A (en) 2019-11-29
TWI615152B (zh) 2018-02-21
AU2013328111A1 (en) 2015-03-12
CA2885800A1 (en) 2014-04-17
KR102584005B1 (ko) 2023-09-27
LT3342785T (lt) 2020-02-10
AU2018200308A1 (en) 2018-02-01
KR102369419B1 (ko) 2022-03-02
US20190008981A1 (en) 2019-01-10
KR20200026323A (ko) 2020-03-10
SI2907824T1 (en) 2018-06-29
JP5953378B2 (ja) 2016-07-20
KR20230086800A (ko) 2023-06-15
TWI870273B (zh) 2025-01-11
HRP20180870T1 (hr) 2018-07-13
TW201420117A (zh) 2014-06-01
US11633493B2 (en) 2023-04-25
TW202448462A (zh) 2024-12-16
JP2018188455A (ja) 2018-11-29
AU2022203560B2 (en) 2025-02-06
JP7170812B2 (ja) 2022-11-14
AU2018200308B2 (en) 2019-11-07
KR20150067149A (ko) 2015-06-17
KR102853456B1 (ko) 2025-09-01
TWI650312B (zh) 2019-02-11
TR201809636T4 (tr) 2018-07-23
ZA201501825B (en) 2022-05-25
MX2019004502A (es) 2019-08-21
KR102417310B1 (ko) 2022-07-05
JP2018008982A (ja) 2018-01-18
LT2907824T (lt) 2018-06-11
US9808537B2 (en) 2017-11-07
JP6186045B2 (ja) 2017-08-23
IL294622A (en) 2022-09-01
SMT202000138T1 (it) 2020-05-08
IL294622B1 (en) 2023-06-01
TWI877062B (zh) 2025-03-11
TWI870276B (zh) 2025-01-11
US10195288B2 (en) 2019-02-05
KR102540419B1 (ko) 2023-06-05
TWI879658B (zh) 2025-04-01
TW202444429A (zh) 2024-11-16
JP2016196484A (ja) 2016-11-24
CN109081871A (zh) 2018-12-25
PL3342785T3 (pl) 2020-09-07
RS60000B1 (sr) 2020-04-30
US20200282073A1 (en) 2020-09-10
ES2671644T3 (es) 2018-06-07
KR20220029776A (ko) 2022-03-08
EP2907824A4 (en) 2016-06-08
JP6371452B2 (ja) 2018-08-08
KR102052319B1 (ko) 2019-12-05
EP2907824A1 (en) 2015-08-19
JP6715888B2 (ja) 2020-07-01
CA3021435A1 (en) 2014-04-17
IL271760A (en) 2020-02-27
CY1122789T1 (el) 2021-05-05
AU2025202668A1 (en) 2025-07-03
PH12018501433A1 (en) 2019-02-27
KR20220146669A (ko) 2022-11-01
US12186310B2 (en) 2025-01-07
US20150297748A1 (en) 2015-10-22
SI3342785T1 (sl) 2020-02-28
BR122021014365B1 (pt) 2022-07-05
US20250049782A1 (en) 2025-02-13
DK2907824T3 (en) 2018-07-23
SG10201804788XA (en) 2018-07-30
KR20210038728A (ko) 2021-04-07
MX2020010964A (es) 2020-11-09
KR101841818B1 (ko) 2018-03-26
TW202233186A (zh) 2022-09-01
NZ746440A (en) 2019-11-29
IL313147A (en) 2024-07-01
TW202448464A (zh) 2024-12-16
KR20230142808A (ko) 2023-10-11
KR20240144454A (ko) 2024-10-02
EP3342785B1 (en) 2019-12-25

Similar Documents

Publication Publication Date Title
KR102087017B1 (ko) 항체-약물 콘주게이트
JP6272230B2 (ja) 親水性構造を含むリンカーで結合させた抗体−薬物コンジュゲート

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20191128

Application number text: 1020187026771

Filing date: 20180914

PA0201 Request for examination
E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20191205

PG1501 Laying open of application
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200303

Application number text: 1020187026771

Filing date: 20180914

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20200304

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20200304

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20230220

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20240219

Start annual number: 5

End annual number: 5